What is Climb Bio, Inc.'s (CLYM) StockRank?

MoatMap's StockRank for Climb Bio, Inc. (CLYM) is 46/100, with a Hold signal. This is a composite score combining Quality (40), Value (26), and Momentum (71) factor ranks across MoatMap's 19,000+ stock universe.

Does Climb Bio, Inc. have an economic moat?

Climb Bio, Inc. (CLYM) has a Quality factor score of 40/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Climb Bio, Inc. a buy, hold, or sell?

MoatMap's current signal for Climb Bio, Inc. (CLYM) is Hold, based on a StockRank of 46/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Climb Bio, Inc. in?

Climb Bio, Inc. (CLYM) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

CLYM

HOLDREMOVE

Climb Bio, Inc. · Healthcare · United States · $649M · Avg Vol: $12M/d

StockRank

P/E (TTM)

—

ROE

-30.9%

D/E

0.0x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Climb Bio is a clinical-stage biotechnology company. It lacks the established cash flows, high ROIC, and proven business model required by our Terry Smith and Warren Buffett lenses, and does not align with our CDMO pricing power theme.

COMPANY DESCRIPTION

Climb Bio, Inc. is a preclinical-stage biotechnology company focused on discovering and developing innovative therapies for unmet medical needs, likely leveraging specific scientific platforms or therapeutic modalities. The company aims to establish a competitive edge through proprietary scientific platforms or novel drug candidates that target specific disease mechanisms. Climb Bio is an emerging biotech firm dedicated to groundbreaking research and development, seeking to create transformative treatments within its specialized therapeutic area.

FINANCIAL SUMMARY

Year	2022	2023	2024	2025	CAGR
Revenue	0	0	0	0	—
EPS	-1.72	-1.30	-1.53	-0.88	—
Shares	27M	28M	67M	48M	+79.8%
Debt	480,000	349,000	532,000	541,000	4.1%
Equity	129M	108M	212M	160M	7.6%
Op CF	-37M	-21M	-16M	-54M	—
Inv CF	34M	69M	-121M	3M	—
Fin CF	0	841,000	131M	-21,000	—

PRICE (1M)+18.6%

SMA 50SMA 200

$11.49

RSI (14)

50.8

52W High

$12.48

From 52W High

0.9%

SCORE BREAKDOWN

Quality

ROIC

-42.2%16.7

ROE

-30.9%24.9

GP/Assets

—N/A

Op. Margin

0.0%40.6

FCF/Assets

-20.4%16.2

Piotroski

—7.2

Int. Cover

—N/A

D/E Ratio

0.00x94.7

Current Ratio

27.86x97.5

Value

P/E (TTM)

—N/A

EV/EBITDA

—N/A

P/FCF

—N/A

P/B

3.7x32.2

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

92%91.2

RS 6M

391%99.7

SMA 50/200

1.88x99.4

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

-46%9.5

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$649M

P/E (Forward)

-10.2x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CLYM are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
CLYM	Climb Bio, Inc.(you)	$649M	46	HOLD
SLDB	Solid Biosciences Inc.	$696M	46	HOLD
IMMX	Immix Biopharma, Inc.	$629M	48	HOLD
ANRO	Alto Neuroscience, Inc.	$710M	47	HOLD
0JDK.L	Iovance Biotherapeutics, Inc.	$638M	43	HOLD
0KCS.L	OPKO Health, Inc.	$734M	44	HOLD
DSGN	Design Therapeutics, Inc.	$671M	40	HOLD
OMER	Omeros Corporation	$807M	50	HOLD
CTNM	Contineum Therapeutics, Inc.	$498M	43	HOLD
CCCC	C4 Therapeutics, Inc.	$405M	47	HOLD

Peer medians: ROE -21.9% · P/E 25.1x · Gross margin 44.3%

Climb Bio, Inc. (CLYM) — Stock Score Summary

Climb Bio, Inc. (CLYM) has a MoatMap StockRank of 46/100 based on Quality (40/100), Value (26/100), and Momentum (71/100) factor scores. The current signal is HOLD. Climb Bio is a clinical-stage biotechnology company. It lacks the established cash flows, high ROIC, and proven business model required by our Terry Smith and Warren Buffett lenses, and does not align with our CDMO pricing power theme.

Key Financial Metrics

Price	$11.49
Market Cap	$649M
P/E (Forward)	-10.19
Price/Book	3.69
Return on Equity	-30.9%
Return on Invested Capital	-42.2%
Debt/Equity	0.32
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-34M

Climb Bio, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Climb Bio, Inc.’s (CLYM) StockRank?: MoatMap’s StockRank for Climb Bio, Inc. (CLYM) is 46/100, with a Hold signal. It is a composite of Quality (40), Value (26), and Momentum (71) factor ranks across MoatMap’s 19,000+ stock universe.
Does Climb Bio, Inc. have an economic moat?: Climb Bio, Inc. (CLYM) has a Quality factor score of 40/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Climb Bio, Inc. a buy, hold, or sell?: MoatMap’s current signal for Climb Bio, Inc. (CLYM) is Hold, based on a StockRank of 46/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Climb Bio, Inc. in?: Climb Bio, Inc. (CLYM) operates in the Healthcare sector, specifically the Biotechnology industry (United States).